在慢性淋巴细胞白血病的前线治疗
Miguel Arguello-Tomas1,2,3,4, Nil Albiol5,6,7,8, Carol Moreno9,10,5,6
1Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, miguelarguellodetomas@gmail.com.
Acta haematologica
|October 29, 2023
概括
慢性淋巴细胞白血病 (CLL) 的治疗已经进步,治疗途径抑制剂 (PI) 现在优先于化疗免疫疗法 (CIT) 作为一线治疗,特别是在高风险患者中.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性淋巴细胞白血病 (CLL) 的治疗环境已经显著发展.
- 近几十年来,新的,更有效的疗法出现了.
- 化疗免疫疗法 (CIT) 是对CLL的传统一线治疗方法.
研究的目的:
- 讨论以前没有接受过治疗的慢性淋巴细胞白血病 (CLL) 患者的管理.
- 突出一线治疗中向途径抑制剂 (PI) 的转变.
主要方法:
- 对前线CLL治疗的当前治疗指南和临床试验数据的审查.
- 化学免疫疗法 (CIT) 和途径抑制剂 (PI) 之间的疗效和毒性比较.
- 专注于具有高风险特征的患者群体,如TP53异常和未变异的IGHV.
主要成果:
- 途径抑制剂 (PI),包括布鲁顿氨酸激酶抑制剂和BCL2抑制剂,与CIT相比,显示出更高的疗效.
- 塑料阻尼剂提供可接受的毒性概况,使它们成为首选选择.
- 在前线CLL管理中,PI的组合越来越重要.
结论:
- 途径抑制剂代表了慢性淋巴细胞白血病前线治疗的重大进展.
- 它们的有效性,特别是在高风险患者中,使它们成为当前的护理标准.
- 随着CLL治疗的不断发展,重点是针对性治疗,而不是传统的化疗.
更多相关视频
11:39Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
Published on: October 23, 2019
11.5K
09:52A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
7.6K
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Primary Lymphoid Organs
1.6K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
1.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
